Recombinant CD19 (Tafasitamab Biosimilar) antibody
This Human Monoclonal antibody specifically detects CD19 (Tafasitamab Biosimilar) in ELISA, BLI, FACS, Func and SPR. It exhibits reactivity toward Human.
Catalog No. ABIN7675648
-15% Promotion 2026
$294.23
save $51.92 (-15 %)
Plus shipping costs $50.00
Shipping to:
United States
Delivery in 10 to 11 Business Days
Quick Overview for Recombinant CD19 (Tafasitamab Biosimilar) antibody (ABIN7675648)
Target
CD19 (Tafasitamab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
Human
Clonality
Monoclonal
Conjugate
This CD19 (Tafasitamab Biosimilar) antibody is un-conjugated
Application
ELISA, Bio-Layer Interferometry (BLI), Flow Cytometry (FACS), Functional Studies (Func), Surface Plasmon Resonance (SPR)
-
-
Expression System
- CHO Cells
-
Purpose
- Anti-CD19 Reference Antibody (tafasitamab)
-
Sequence
- EVQLVESGGG LVKPGGSLKL SCAASGYTFT SYVMHWVRQA PGKGLEWIGY INPYNDGTKY NEKFQGRVTI SSDKSISTAY MELSSLRSED TAMYYCARGT YYYGTRVFDY WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELLG GPDVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVQFN WYVDGVEVHN AKTKPREEQF NSTFRVVSVL TVVHQDWLNG KEYKCKVSNK ALPAPEEKTI SKTKGQPREP QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP MLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K,DIVMTQSPAT LSLSPGERAT LSCRSSKSLQ NVNGNTYLYW FQQKPGQSPQ LLIYRMSNLN SGVPDRFSGS GSGTEFTLTI SSLEPEDFAV YYCMQHLEYP ITFGAGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
-
Characteristics
- Anti-CD19 Reference Antibody (tafasitamab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 144.56 kDa.
-
Purity
- >95 %
-
Isotype
- IgG1
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Comment
-
Therapeutic Agents by Target and Mechanism: CD19 inhibitors, ADCC, Antibody-dependent phagocytosis
Conditions: Acute lymphoblastic leukemia Acute myeloid leukemia Chronic Lymphocytic Leukemia Diffuse Large B-Cell Lymphoma Non-Hodgkin's Lymphoma
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Concentration
- 1 mg/mL
-
Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
Storage
- 4 °C,-80 °C
-
Storage Comment
- +4°C,-80°C
-
-
- CD19 (Tafasitamab Biosimilar)
-
Target Type
- Biosimilar
-
Molecular Weight
- 144.56 kDa
-
UniProt
- P15391
Target
-
You are here:
